4.31 0.02 (0.47%) | 02-18 16:00 | |||||||||||||
|
|
Short term | ![]() ![]() ![]() |
|||
Mid term | ![]() |
|||
Targets | 6-month : | 5.53 | 1-year : | 6.46 |
Resists | First : | 4.73 | Second : | 5.53 |
Pivot price | 4.1 ![]() |
|||
Supports | First : | 3.99 | Second : | 3.53 |
MAs | MA(5) : | 4.25 ![]() |
MA(20) : | 4.05 ![]() |
MA(100) : | 3.63 ![]() |
MA(250) : | 3.7 ![]() |
|
MACD | MACD : | 0.1 ![]() |
Signal : | 0.1 ![]() |
%K %D | K(14,3) : | 62.2 ![]() |
D(3) : | 60 ![]() |
RSI | RSI(14): 62.1 ![]() |
|||
52-week | High : | 5.62 | Low : | 2.86 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ MURA ] has closed below upper band by 32.6%. Bollinger Bands are 53% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.
If tomorrow: | Open lower | Open higher |
High: | 4.38 - 4.4 | 4.4 - 4.41 |
Low: | 4.21 - 4.23 | 4.23 - 4.24 |
Close: | 4.28 - 4.31 | 4.31 - 4.33 |
Mural Oncology Plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops engineered interleukin-18 and tumor-targeted interleukin-12 programs. The company was incorporated in 2017 and is based in Dublin, Ireland. As of November 15, 2023, Mural Oncology Plc operates as a former subsidiary of Alkermes plc.
Tue, 18 Feb 2025
Exclusive: Mural Oncology Unveils Next-Gen Cancer Treatment Strategy at Major Healthcare Conference - StockTitan
Tue, 18 Feb 2025
Mural Oncology to Present at the TD Cowen 45th Annual Health Care Conference - The Manila Times
Mon, 17 Feb 2025
Mural Oncology plc (NASDAQ:MURA) Short Interest Update - MarketBeat
Mon, 10 Feb 2025
Mural Oncology (NASDAQ:MURA) Shares Up 8.8% - Should You Buy? - MarketBeat
Mon, 27 Jan 2025
Jones Trading Initiates Coverage of Mural Oncology (MURA) with Buy Recommendation - MSN
Thu, 09 Jan 2025
Mural Oncology Expands Pipeline with Two Novel Cancer Therapies, Advances Key Clinical Trials - StockTitan
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 17 (M) |
Shares Float | 13 (M) |
Held by Insiders | 1.4 (%) |
Held by Institutions | 59.9 (%) |
Shares Short | 397 (K) |
Shares Short P.Month | 436 (K) |
EPS | -9.03 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 10.22 |
Profit Margin | 0 % |
Operating Margin | 0 % |
Return on Assets (ttm) | -85.4 % |
Return on Equity (ttm) | -183.9 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | -9.15 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -140 (M) |
Levered Free Cash Flow | -82 (M) |
PE Ratio | -0.48 |
PEG Ratio | 0 |
Price to Book value | 0.42 |
Price to Sales | 0 |
Price to Cash Flow | -0.53 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |